Endosonography-guided coloenterostomy (CE) significantly enhances outcomes for patients with small-bowel ileus due to peritoneal carcinomatosis. In a cohort of 17 patients, CE achieved a 94% technical success rate, with most experiencing symptom relief and improved quality of life. Notably, overall survival spanned 86 days compared to 14 days with conventional gastrostomy. Moreover, over half had […]
Category: Cytoreductive Surgery & Peritoneum
Tailored Surveillance Improves Outcomes in Mucinous Appendix Cancer
Mucinous appendix cancer (MAC) recurrence varies significantly by histology and critical postoperative periods. In a study of 385 patients, relapse risk was highest shortly after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: 1.0, 2.6, and 3.8 per 10 person-years for low-grade, high-grade, and signet-ring cell cancers, respectively. Researchers recommend individualized follow-up schedules every 5.5 to 18 […]
CRS Plus HIPEC Outperforms CRS Alone in Quality of Life for Cancer Patients
Patients with colorectal cancer receiving cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy (CRS plus HIPEC) experience significantly improved quality of life (QoL) compared to those undergoing CRS alone. Results indicate a notable minimal clinically important difference (MCID) favoring the HIPEC group, with improvement often evident within three months. Deterioration in MCID correlates with factors such as […]
Cytoreductive surgery halves death risk in colorectal peritoneal metastasis.
Cytoreductive surgery markedly improves overall survival in colorectal peritoneal metastasis compared to modern systemic therapies alone. A systematic review of 3316 patients reveals a pooled hazard ratio of 0.447, indicating nearly a 55% reduction in the risk of death. This benefit persists across various palliative treatments, demonstrating robust effectiveness despite variations in therapy intensity. With […]
Enhanced diagnostic accuracy for peritoneal metastasis in gastric cancer
A novel machine learning-driven surface-enhanced Raman spectroscopy (SERS) platform showcased remarkable diagnostic prowess in identifying peritoneal metastasis in gastric cancer patients. The PCA-LDA model achieved an accuracy of 95.7%, sensitivity of 87.0%, and specificity of 95.5%, all significantly outperforming traditional methods like exfoliative cytology and CT scans. This innovative approach promises to streamline and enhance […]
Multimodal therapies enhance survival in advanced cancer patients
Researchers found that cytoreductive surgery combined with multimodal therapies significantly improved overall survival and progression-free survival in patients with advanced ovarian, colorectal, and gastric cancers. Analyzing data from 13 studies involving nearly 4,000 patients, the experimental group showed a 14% decrease in mortality risk and enhanced survival rates, although associated with a higher risk of […]
Higher compliance with ERAS pathways improves postoperative outcomes
Enhanced recovery pathways significantly reduced postoperative morbidity and LOS in cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Among 150 patients studied, average compliance reached 77.6%, showing a notable negative correlation with postoperative complications and delays in return to intended oncological therapy. Specifically, patients with compliance below 71.6% faced increased morbidity. These findings support the efficacy of […]
Advances in treating peritoneal oligometastasis in gastric cancer
Peritoneal metastasis from gastric cancer significantly impacts prognosis, but advancements in diagnostic and therapeutic strategies are transforming patient outcomes. A peritoneal cancer index (PCI) threshold of ≤6 identifies patients with oligometastasis who may benefit from aggressive therapies. Cytoreductive surgery coupled with hyperthermic intraperitoneal chemotherapy remains essential for curative intent. Emerging techniques like normothermic and pressurized […]
New guidelines prioritize systemic therapy for colorectal cancer with peritoneal metastases
Consensus guidelines for managing colorectal cancer with peritoneal metastases emphasize early referral to specialized centers. A national panel achieved over 90% consensus on clinical pathways, favoring systemic therapy over upfront surgery in synchronous cases. In metachronous cases, risk stratification was updated. Although the overall evidence remains low, the guidelines represent significant progress in addressing optimal […]
Cytoreductive surgery improves survival in metastatic colorectal cancer.
National trends indicate that the utilization of cytoreductive surgery (CRS) for metastatic colorectal cancer (mCRC) increased from 33.1% in 2004 to 38.3% in 2015. In a cohort of 88,593 patients, those undergoing CRS exhibited significantly better overall survival (OS) compared to non-surgical patients, with median OS at 34.4 months, versus 13.2 months for no surgery. […]